CBAY has a higher average analyst price target than % of Healthcare stocks. Is CBAY a Buy, Hold or Sell? See the POWR Ratings now! Most Popular Stories. CBAY Stock Overview · Trading at % below our estimate of its fair value · Revenue is forecast to grow % per year · Shareholders have been diluted in the. News · Trending: Gilead Sciences to buy CymaBay for $ Billion · CymaBay's stock surges as Gilead reaches $ billion deal for liver-drug developer · Gilead. View analyst opinion as to whether the stock is a strong buy, strong sell or hold, based on analyst Month CBAY price targets. No data available. Technical. Sorry, CBAY is unavailable at this time. None of the information presented should be construed as an offer to sell or buy any particular security. As always.
The Fund Sentiment Score (fka Ownership Accumulation Score) finds the stocks that are being most bought by funds. Great West Life Assurance Co /can/, 0. CymaBay is sprinting to the finish line with a treatment for a serious liver disease and CBAY stock is on a massive run. Yahoo | December 28, Industry. The consensus rating for CymaBay Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CBAY. Cymabay Therapeutics has an average buy rating and a price target range of $8 to $17, according to analysts polled by Capital IQ. Price: , Change: + Rating. Strong Buy. Moderate Buy. Hold. Moderate Sell. Strong Sell. # of Analysts Traders work on the floor of the New York Stock Exchange during morning. Is Cymabay Therapeu a Good Stock to Buy? Determining whether Cymabay Therapeu—or any stock—is a good buy requires comprehensive analysis. To evaluate its. Is CymaBay Therapeutics a good stock to buy? Based on our CymaBay Therapeutics stock forecast, CymaBay Therapeutics stock is currently not a good stock to buy. Analyst Ratings. The average analyst rating for GILD stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According. What analysts recommend for CBAY stock, on a scale from 1(buy) to 5(sell). Buy. Strong Buy 29%. Buy 24%. Hold 47%. Sell 0%. Strong Sell 0%. CymaBay Therapeutics. Strong Buy. Forecast Fundamentals Insider Trading Signals Historical Prices Click to get the best stock tips daily for free! NVDA $
Tomorrow's movement Prediction of CymaBay Therapeutics Inc. CBAY is showing signs of weakness. Either there is a negative sentiment following this stock or an. Is CymaBay Therapeutics stock a Buy, Sell or Hold? CymaBay Therapeutics stock has received a consensus rating of buy. The average rating score is and is. Strong buy ratings: Buy ratings: Hold ratings: Sell ratings: Strong sell ratings. Get the latest CymaBay Therapeutics Inc. (CBAY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. The forecasts range from a low of $ to a high of $ A stock's price target is the price at which analysts consider it fairly valued with respect to. Cymabay Therapeutics has an average buy rating and a price target range of $8 to $17, according to analysts polled by Capital IQ. Price: , Change: + With no established resistance level above the current price and a strong support at $, CBAY's price action has room to explore new highs. Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cymabay Therapeu is 'Not Rated'. You can watch CBAY and buy and sell other stock and options commission-free on Robinhood. Change the date range, see whether others are buying or selling.
Get stock insights, analysis and discussion about CymaBay Therapeutics Inc (NDAQ:CBAY). Join the CBAY discussion on Canada's largest online investor. Why CymaBay Therapeutics Stock Is Jumping Today. Keith Speights | Sep 8, The momentum continues after CymaBay reported great clinical results on Thursday. USA. Stock. Cymabay Therapeu · Summary · Profile · CBAYDelisted Stock, USD In that case, they are not buying Cymabay because the equity is a good. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According. Stock name: CBAY, Stock Code: CBAY, Company: CymaBay Therapeutics, Inc Debt Buy-back Programme Set to Improve Liquidity, Says US Treasury Official.
investment advice to buy or sell securities. Any historical returns, expected returns or probability /investments/stocks/cymabay-therapeutics-inc-cbay. Why is CymaBay (CBAY) Stock Up 25% Today? RTTNews d. CymaBay Announces FDA CymaBay Therapeutics (CBAY) Gets a Buy from Piper Sandler. PR Newswire. FAQs on CymaBay Therapeutics Inc. Can I Buy CymaBay Therapeutics Inc Shares in India?